Lisa Nadal | Philochem

2026 Swiss Chemical Society (SCS) Industrial Science Award for Samuele Cazzamalli, Head of Research at Philochem

by Lisa Nadal | Nov 28, 2025 | Press Releases, Scientific

Dr. Samuele Cazzamalli, Head of Research at Philochem, will be awarded the Industrial Science Award 2026 from the Swiss Chemical Society His research has focused on the discovery of novel tumor-targeting diagnostic and therapeutic agents through the use of DNA-Encoded...

Philochem to attend the Festival of Biologics 2025 in Basel on September 30-October 2, 2025

by Lisa Nadal | Oct 1, 2025 | Events, Scientific

Dr. Emanuele Puca will give an oral presentation entitled: “Antibody-cytokine Fusions for Cancer Therapy: Late-Stage Clinical Results” Dr. Roberto de Luca will give an oral presentation entitled: “Engineering Antibody-Cytokine Fusion Proteins (Immunocytokines) for...

Philochem AG Announces Completion of Antitrust Clearance and Closing of the OncoACP3 Licensing Agreement with RayzeBio, a Bristol Myers Squibb Company, With a Potential Value of up to $1.35 Billion Plus Royalties

by Lisa Nadal | Aug 18, 2025 | Investors, Press Releases

For more details

Philogen is pleased to invite you to a webinar with Prof. Dario Neri, taking place today, June 11, at 11:00 ET | 17:00 CET.

by Lisa Nadal | Jun 11, 2025 | Events, Investors

Following last night’s announcement regarding OncoACP3, we are pleased to invite you to a webinar with Prof. Dario Neri, taking place today, June 11, at 11:00 ET | 17:00 CET. Please contact us at IR@philogen.com or follow the link to register to the...

Philochem AG Announces the Licensing of Worldwide Rights to OncoACP3, a novel Radiopharmaceutical Therapeutic and Diagnostic Agent targeting Prostate Cancer, to RayzeBio, a Bristol-Myers Squibb Company, for a potential value of up to $1.35bn plus royalties.

by Lisa Nadal | Jun 10, 2025 | Press Releases

More details

« Older Entries

2026 Swiss Chemical Society (SCS) Industrial Science Award for Samuele Cazzamalli, Head of Research at Philochem

Philochem to attend the Festival of Biologics 2025 in Basel on September 30-October 2, 2025

Philochem AG Announces Completion of Antitrust Clearance and Closing of the OncoACP3 Licensing Agreement with RayzeBio, a Bristol Myers Squibb Company, With a Potential Value of up to $1.35 Billion Plus Royalties

Philogen is pleased to invite you to a webinar with Prof. Dario Neri, taking place today, June 11, at 11:00 ET | 17:00 CET.

Philochem AG Announces the Licensing of Worldwide Rights to OncoACP3, a novel Radiopharmaceutical Therapeutic and Diagnostic Agent targeting Prostate Cancer, to RayzeBio, a Bristol-Myers Squibb Company, for a potential value of up to $1.35bn plus royalties.

Recent Posts